Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC
As reported in The Lancet Oncology by Brunetti et al, a post hoc analysis of the phase III PACIFIC trial showed that baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes among patients with unresectable stage III non–small cell lung cancer (NSCLC) treated with durvalumab after chemoradiotherapy, but not among those who received placebo.
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
A research team has reported that a groundbreaking pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
In a phase I clinical trial, treatment with the investigational FcRH5×CD3 bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma—many of whom had already been through multiple other cancer treatments—and produced a median duration of response of 11.2 months before disease progression.
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E–Positive Differentiated Thyroid Cancer
In a global phase III trial reported in The Lancet Oncology by Gao et al, dabrafenib plus trametinib significantly improved progression-free survival and overall response rate compared with placebo in previously treated patients with locally advanced or metastatic, radioactive iodine–refractory, BRAF V600E–positive differentiated thyroid cancer.
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The approval comes ahead of the original target action date of September 18, 2026, and follows the FDA's Breakthrough Therapy and Orphan Drug designations.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura L. Gillison, MD, PhD Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct...
Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
Germline genetics impact the safety and efficacy of engineered chimeric antigen receptor (CAR) T-cell therapies in patients with hematologic malignancies, according to study findings published in Science Immunology. “These findings have important implications for understanding how CAR T cells...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 years and older who are at average risk for the disease. The test is produced by Freenome; Abbott will exclusively commercialize the test in the...
Electronic Prior Authorization Requirements for Drugs
The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. If finalized, this rule will require...
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Among patients with high-risk hematologic malignancies who underwent hematopoietic cell transplantation with posttransplant cyclophosphamide, mismatched unrelated donor (MMUD) transplantation was associated with lower relapse rates than matched related donor (MRD) transplantation while showing...
